Monday, October 26, 2026 · Daily editionET --:--:--

MedicalTable-mounted surgical robot

Ottava

by Johnson & Johnson

Ottava is a surgical robot from Johnson & Johnson whose four arms are built into the operating table instead of standing on separate carts. It is meant for soft-tissue keyhole surgery in the belly. Johnson & Johnson press release, 22 July 2026

5

Stage 5 of 5

Regulator-cleared or mass market

Which rule placed it
Evidence
Company-reported only
Human help
Not disclosed
Last milestone
22 July 2026

01Can I get it?

Yes, in places

Where it works today
Authorized in the US since July 2026 for 10 upper-belly operations. Johnson & Johnson said it would launch it first with selected US customers. Johnson & Johnson press release, 22 July 2026
Published price
No published price in our sources.
Human help
The maker hasn't said whether people help it remotely.

03Promised vs delivered

What the maker said, and when

Dated targets the maker set in public, against what has happened since.

  • SaidOct 2021

    First human trials in second half of 2024

    After a delay, Johnson & Johnson said first-in-human trials of Ottava would start in the second half of 2024. MedTech Dive, 28 Oct 2021

    Missed

    The FDA allowed the trial in November 2024, but the first operations were done in April 2025.

04Safety and incidents

What has gone wrong

No crashes, recalls or regulator reports in our sources. That is not proof none happened; we add them when a regulator or trusted outlet reports one.

How we placed it

The rule, not an opinion

Stages are worked out by published rules from the dated milestones above. We never rate robots, and no maker can pay to change a stage.

  1. 5

    Regulator-cleared or mass marketThis robot

    A regulator has cleared it where approval applies: FDA clearance or approval for a medical robot, a permit to run with no one aboard for a self-driving vehicle, or an FAA approval for routine drone flights. Or: Widely sold: sales in the hundreds of thousands, or a product category you can buy in ordinary shops.

    Placed by: The FDA granted Ottava De Novo authorization for 10 general surgery operations in the upper belly, including gastric bypass, gallbladder removal and hiatal hernia repair (22 July 2026).

  2. 4

    Paying customers

    Delivered to customers who pay for it, beyond a trial, or a paid service the public can use.

  3. 3

    Pilot

    Working with a named customer in a real setting, as a trial.

  4. 2

    Pre-orders

    Orders, reservations or deposits taken, with nothing delivered yet.

  5. 1

    Demo only

    Shown in videos, staged events or a factory, with no units working for customers.

What we couldn't confirm. We did not find the DEN number of the July 2026 De Novo in a source we opened. The hint's njbiz report was not opened; the date and procedures were confirmed from J&J's own release. J&J first said trials would start in the second half of 2022.